Direkt zum Inhalt
Merck
  • Clindamycin phosphate 1.2%- tretinoin 0.025% gel: vehicle characteristics, stability, and tolerability.

Clindamycin phosphate 1.2%- tretinoin 0.025% gel: vehicle characteristics, stability, and tolerability.

Cutis (2008-06-12)
James Q Del Rosso, Waranush Jitpraphai, Sanjay Bhambri, Saira Momin
ZUSAMMENFASSUNG

An aqueous gel formulation containing solubilized clindamycin phosphate 1.2% and a stable combination of both solubilized and crystalline tretinoin 0.025% (clin/tret) has been evaluated in 3 pivotal phase 3 studies, among other studies including a 52-week trial. The pivotal studies enrolled 4550 participants 12 years and older with mild, moderate, and severe acne vulgaris. The combination clin/tret gel was effective in reducing both inflammatory and noninflammatory lesions and was well-tolerated. This article reviews important vehicle characteristics of the combination gel as well as formulation stability and tolerability data that are potentially clinically relevant.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Retinsäure, ≥98% (HPLC), powder
Supelco
Retinsäure, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Clindamycin-Phosphat, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Tretinoin, United States Pharmacopeia (USP) Reference Standard
USP
Clindamycinphosphat, United States Pharmacopeia (USP) Reference Standard
Clindamycinphosphat, European Pharmacopoeia (EP) Reference Standard
Tretinoin, European Pharmacopoeia (EP) Reference Standard